Daily Bulletin

PR Newswire

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma's DEP® cabazitaxel is a water soluble, polysorbate-80 free formulation, without requirement for pre-treatment with steroids nor G-CSF to reduce the risk of severe bone marrow toxicity.

In preclinical and clinical studies, DEP® cabazitaxel has shown an improved side effect profile, notably markedly reduced bone marrow toxicity demonstrated by lower rates of severe neutropenia, thrombocytopenia, and severe anaemia, which are experienced by a significant proportion of Jevtana® treated patients.

The composition of matter patent builds on Starpharma's suite of existing international patents for DEP® cabazitaxel. It specifically covers a DEP® dendrimer conjugated to multiple cabazitaxel drug molecules via a particular releasable linker, with a patent term to 2039 and potential for a 5-year extension.

Starpharma CEO, Dr Jackie Fairley, commented: "The grant of this new US patent illustrates the unique and compelling benefits of Starpharma's DEP® drug delivery technology and DEP® cabazitaxel. We look forward to completing the phase 2 clinical program for DEP® cabazitaxel, in parallel with commercial licensing discussions."

DEP® cabazitaxel is in late phase 2 clinical development, recruiting patients with solid tissue tumours, including prostate, ovarian and gastro-oesophageal cancers. 

Encouraging efficacy signals have been observed in multiple tumour types, including in prostate cancer where radiological responses, significant reductions in prostate-specific antigen (PSA) and no new bone metastases were observed. These efficacy signals were observed despite patients having been heavily pre-treated with an average of 30 prior cycles of treatment, and in some cases with more than 100 cycles and up to 10 different treatment regimens. Patients treated with DEP® cabazitaxel have also exhibited encouraging efficacy signals in gastro-oesophageal, ovarian, cholangiocarcinoma, lung and head and neck cancers.

DEP® cabazitaxel was developed using Starpharma's proprietary DEP® drug delivery platform, used by the company and partners to create novel nanoparticle formulations of existing and new drugs to enhance their therapeutic and commercial value.  DEP® drug delivery is applicable to a wide range of drugs in oncology and other therapeutic areas. Starpharma has three phase 2 clinical-stage DEP® assets, multiple preclinical DEP® programs, and several DEP® commercial partnerships with companies, including AstraZeneca, Chase Sun and Merck & Co., Inc., to develop DEP® versions of their products or ADCs.

investor.relations@starpharma.com 

Cision View original content:https://www.prnewswire.com/news-releases/us-patent-and-trademark-office-grants-new-patent-for-dep-cabazitaxel-one-of-starpharmas-phase-2-clinical-stage-cancer-treatments-301377264.html

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/3507796_CN07796_0

What a Traveler Needs to Know Before a Road Trip in Australia

arrow_forward

Tips for Selecting the Right Bath Pillows for Tub

arrow_forward

Plumber Hacks to Keep Your Drain Clear

arrow_forward

The Conversation
INTERWEBS DIGITAL AGENCY

Business News

What you need to know before buying any business

Before buying any business, the first thing you need to know is how long the business has been in operation. It is because you'll be investing time, money, and other resources into the business, i...

Daily Bulletin - avatar Daily Bulletin

5 Reasons your Business Needs Lean Consulting

If you want to implement the lean management system or you've just started, you might be considering working with a firm that's an expert in lean consulting to reinforce your training, execution, ...

NewsServices.com - avatar NewsServices.com

Invest In The Best Trading Platforms In Australia

A dependable trading platform would help you streamline your trading process and increase your return on investment. When it comes to selecting a stockbroker, Australians have a lot of options. Th...

Daily Bulletin - avatar Daily Bulletin